Patents Examined by Dong Jiang
  • Patent number: 9850294
    Abstract: A protein comprising an amino acid sequence having at least 97% homology to SEQ ID NO: 1. The amino acid sequence comprises valine at position 60, glycine at position 123 and lysine at position 109 and the protein binds hIL17A.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 26, 2017
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV, LTD.
    Inventors: Amir Aharoni, Marianna Zaretzky
  • Patent number: 9845353
    Abstract: The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 19, 2017
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
  • Patent number: 9815880
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Patent number: 9796777
    Abstract: The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumor. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 24, 2017
    Assignee: CANIMGUIDE THERAPEUTICS AB
    Inventors: Leif Håkansson, Birgitta Clinchy
  • Patent number: 9784728
    Abstract: The present invention refers to a fluorescent fusion polypeptide capable of changing its localization within the cell from the cell cytoplasmic membrane to the retention vesicles, upon an increase in the concentration of second messengers within the cell cytoplasm, comprising a membrane localization peptide, a second messenger transduction protein binding peptide, a reticulum retention signal and a fluorescent peptide wherein: a. the membrane localization peptide is located at the N-terminus of the fluorescent fusion polypeptide and is physically bound, optionally through a linker, to the fluorescent peptide, which in turn is physically bound, optionally through a linker, to the second messenger transduction protein binding peptide; and b. the second messenger transduction protein binding peptide is physically bound, optionally through a linker, to the reticulum retention signal, which in turn is located at the C-terminus of the fluorescent fusion polypeptide.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: October 10, 2017
    Assignee: INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS S.L.
    Inventors: Danel Kortazar Zabala, Aida Clarisa Salado Pogonza, Jorge Gámiz Mata, Meritxell Roura Ferrer, Rosa Mella López, Patricia Villacé Lozano
  • Patent number: 9783606
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 10, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Patent number: 9771420
    Abstract: The present invention relates neutralizing epitopes of IL-17A and IL-17F and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Thomas Allen Ceska, Alistar James Henry, Jiye Shi
  • Patent number: 9744234
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., 1L-1 7 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 29, 2017
    Assignee: Novartis AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • Patent number: 9725506
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: August 8, 2017
    Assignees: ZYMOGENETICS, INC., UNIVERSITY OF WASHINTON
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Patent number: 9714951
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 25, 2017
    Assignee: INSTITUT PASTEUR
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Patent number: 9714292
    Abstract: The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 25, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Jens Fischer, Hubert Kettenberger, Maximiliane Koenig, Stefan Lorenz, Joerg Moelleken
  • Patent number: 9708401
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Mark W. Rixon, Scott R. Presnell
  • Patent number: 9688753
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Patent number: 9683036
    Abstract: Humanized antibodies specific to human interleukin 20 (IL-20) and uses thereof in treating diseases associated with the IL-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.
    Type: Grant
    Filed: October 29, 2013
    Date of Patent: June 20, 2017
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, Naoya Tsurushita, Shankar Kumar
  • Patent number: 9663572
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: May 30, 2017
    Assignee: ZYMOGENETICS INC.
    Inventors: Stephen R. Jaspers, Scott R. Presnell
  • Patent number: 9655964
    Abstract: Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease are provided.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: May 23, 2017
    Assignee: AbbVie Inc.
    Inventors: Jennifer Perez, Suju Zhong, Lucia Eaton, Anca Clabbers, Chung-Ming Hsieh, Lorenzo Benatuil, Yuliya Kutskova, John E. Memmott, Margaret Hugunin, Alyssa Brito
  • Patent number: 9650437
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignee: NOVIMMUNE S.A.
    Inventors: Krzysztof Masternak, Olivier Leger
  • Patent number: 9631015
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 25, 2017
    Assignee: UCB Pharma S.A.
    Inventors: Richard Evan Gelinas, Mitra Choudhury Singhal, Yi Zhang, Andrew George Popplewell, Ralph Adams
  • Patent number: 9592267
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: March 13, 2003
    Date of Patent: March 14, 2017
    Assignee: MERCK SERONO SA
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat
  • Patent number: 9566313
    Abstract: The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of peripheral vascular diseases. The invention further relates to the use of an IL-18 inhibitor for prevention of limb amputation.
    Type: Grant
    Filed: June 1, 2010
    Date of Patent: February 14, 2017
    Assignees: MERCK SERONO SA, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Yolande Chvatchko, Alain Tedgui, Ziad Mallat